Intrauterine devices (IUDs) refer to small T-shaped plastic or copper birth control devices which are inserted into the uterus. These devices prevent pregnancy by stopping sperm from reaching and fertilizing the eggs. The size of IUDs is similar to that of a match stick and their arms are folded flat so that they fit properly in the uterus. These devices are rapidly gaining popularity across the globe as they are effective, safe, long-acting and eliminate the need for other contraceptives. However, there are some adverse effects attached to the use of IUDs which include spotting, uterus perforation, irregular menstrual pattern and pelvic inflammatory diseases. According to the latest report by IMARC Group, titled “Intrauterine Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023”, the global intrauterine devices market reached a value of around US$ 3.7 Billion in 2017.
Over the years, it has been observed that more than a half of the pregnancies are mistimed, unwanted and unintended. On account of this, several governments and non-profit organizations are promoting the use of IUDs in confluence with educating the people about birth control measures and family planning. Moreover, various awareness programs are expected to increase the sales of IUDs in the upcoming years. Additionally, the act of repealing Affordable Care Act (ACA) in the United States has encouraged a large section of women to choose for long-acting reversible contraception (LARC), such as IUDs, due to the lack of access to abortion and rising copayment. This is further supported by technological innovations, such as reusable and postpartum IUDs, which are anticipated to stimulate the market growth. Looking forward, the market value is projected to reach about US$ 4.6 Billion by 2023, expanding at a CAGR of 3.8 % during 2018-2023.
- Based on product, the market has been segmented as hormonal and copper IUDs. Currently, hormonal IUDs dominate the market, holding the largest share.
- On the basis of end-use segment, the report has segregated the market into hospitals, gynaecology clinics, community healthcare and others.
- The report has segmented the global intrauterine devices market on the basis of region into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
- The competitive landscape of the market has also been examined with some of the key players being Actavis, Bayer, Teva Pharmaceuticals, Allergan, Eurogine, OCON Medical, Pregna, HLL Lifecare, HRA Pharma, ANI Pharmaceuticals, Besins HealthCare, SMB, etc.
This report provides a deep insight into the global intrauterine devices market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the intrauterine devices market in any manner.
Key Questions Answered in This Report:
- How has the global intrauterine devices market performed so far and how will it perform in the coming years?
- What are the key regions in the global intrauterine devices market?
- Which are the popular products in the global intrauterine devices market?
- What are the key end-use segments in the global intrauterine devices market?
- What are the various stages in the value chain of the global intrauterine devices market?
- What are the key driving factors and challenges in the global intrauterine devices market?
- What is the structure of the global intrauterine devices market and who are the key players?
- What is the degree of competition in the global intrauterine devices market?
- How are intrauterine devices manufactured?